Sana Biotechnology, Inc. Common Stock (SANA) Stock
NASDAQ · SANA
2.92
Fundamentals
Market cap
$881.62M
Price / Earnings ratio
-4.2x
Price / Sales ratio
N/A
Price / Book ratio
5.7x
Return on assets
-61.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Stocktwits
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
NeutralSANASeptember 28, 2026
StocktwitsNeutral
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
SANA

Zacks Investment Research
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
NeutralSANAJuly 20, 2026
Zacks Investment ResearchNeutral
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
SANA

Zacks Investment Research
Sana (SANA) Upgraded to Buy: Here's What You Should Know
NeutralSANAJuly 15, 2026
Zacks Investment ResearchNeutral
Sana (SANA) Upgraded to Buy: Here's What You Should Know
SANA

Stocktwits
SANA Stock Rallies 24% After Hours — How Much Is Mayo Clinic Investing In The Company?
NeutralSANAApril 13, 2026
StocktwitsNeutral
SANA Stock Rallies 24% After Hours — How Much Is Mayo Clinic Investing In The Company?
SANA
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
500M330M165M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-244.2M
Net incomeEarnings
EPS forecast
Actual EPS
$-0.16
$-0.21
Q2FY25
$-0.15
$-0.19
Q3FY25
$-0.13
Q4FY25
$-0.11
Q1FY26
$-0.12
Q2FY26
The market is expecting earnings per share of -$0.12 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Stocktwits
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
NeutralSANASeptember 28, 2026
StocktwitsNeutral
Stocktwits Pharma Pulse: Lilly, Novo Lead A Busy Week — Here Are The Stocks And Readouts To Watch
SANA

Zacks Investment Research
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
NeutralSANAJuly 20, 2026
Zacks Investment ResearchNeutral
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
SANA

Zacks Investment Research
Sana (SANA) Upgraded to Buy: Here's What You Should Know
NeutralSANAJuly 15, 2026
Zacks Investment ResearchNeutral
Sana (SANA) Upgraded to Buy: Here's What You Should Know
SANA

Stocktwits
SANA Stock Rallies 24% After Hours — How Much Is Mayo Clinic Investing In The Company?
NeutralSANAApril 13, 2026
StocktwitsNeutral
SANA Stock Rallies 24% After Hours — How Much Is Mayo Clinic Investing In The Company?
SANA

Zacks Investment Research
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
NeutralSANAFebruary 20, 2026
Zacks Investment ResearchNeutral
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
SANA

Zacks Investment Research
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know
NeutralSANAJanuary 30, 2026
Zacks Investment ResearchNeutral
Sana Biotechnology (SANA) Is Up 5.46% in One Week: What You Should Know
SANA

Zacks Investment Research
Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet
NeutralSANAJanuary 23, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Think Sana (SANA) Could Surge 74.2%: Read This Before Placing a Bet
SANA

Zacks Investment Research
Three Genomics Stocks Worth Tracking This Year
NeutralSANAJanuary 6, 2026
Zacks Investment ResearchNeutral
Three Genomics Stocks Worth Tracking This Year
SANA

Zacks Investment Research
Top 3 Genomics Stocks to Consider for Your Portfolio
NeutralSANANovember 18, 2025
Zacks Investment ResearchNeutral
Top 3 Genomics Stocks to Consider for Your Portfolio
SANA

Zacks Investment Research
All You Need to Know About Sana (SANA) Rating Upgrade to Buy
NeutralSANANovember 12, 2025
Zacks Investment ResearchNeutral
All You Need to Know About Sana (SANA) Rating Upgrade to Buy
SANA
About Sana Biotechnology, Inc. Common Stock
Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses on identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 2018 and is headquartered in Seattle, WA.
SectorHealthcare
IndustryBiotechnology
Employees142
CEODr. Steven D. Harr M.D.
IPO DateFeb 3, 2021
HeadquartersSeattle, WA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Steven D. Harr M.D. | President, CEO & Director | 1970 |
| Mr. Brian D. Piper M.B.A. | Executive VP & CFO | 1972 |
| Ms. Susan Wyrick | Treasurer, Principal Accounting Officer and Senior VP of Finance & Accounting | 1973 |
| Mr. Snehal Patel | Senior VP & Chief Technical Officer | — |
| Dr. Dhavalkumar D. Patel M.D., Ph.D. | Executive VP & Chief Scientific Officer | 1961 |
| Mr. Aaron M. Grossman | Executive VP, Chief Legal Officer & Corporate Secretary | 1972 |
| Ms. Debra Wisdom | VP & Head of People | — |
| Dr. Gary Meininger M.D. | Chief Medical Officer | — |
| Dr. Yuko Soneoka J.D., Ph.D. | Head of Intellectual Property | — |
| Mr. John Gerecitano M.D., Ph.D. | Head of Oncology Research & Development | — |
Fundamentals
Valuation
Market cap$881.62M
Price-to-sales ratioN/A
Price-to-book value5.73
Price-earnings ratio-4.20
Return on Equity-162.00%
Return on SalesN/A
Return on Assets-61.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.76
Income Statement
Average volume3,730,645
EBITDA$-221.09M
1 year high (52w)$6.55
1 year low (52w)$2.61
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsStrong Sell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$6.00
Est return
104.08%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.5 | -2.6 | -15.1 | -12.1 | ||||||||
| 2022 | -43.8 | -26.7 | +37.0 | -13.0 | -34.4 | +29.4 | +2.6 | +11.6 | -11.2 | -3.5 | -14.3 | -10.8 |
| 2023 | +22.3 | -22.1 | -8.9 | +64.3 | +10.1 | -2.3 | -3.0 | -6.6 | -27.5 | -17.3 | +31.4 | +1.0 |
| 2024 | +30.7 | +72.2 | -11.3 | -11.1 | -22.1 | -30.1 | +11.3 | +12.9 | -25.7 | -17.5 | -24.0 | -42.8 |
| 2025 | +95.2 | -14.7 | -30.9 | +26.7 | +14.2 | +24.1 | +43.5 | -21.7 | +25.0 | +33.8 | -5.9 | +1.8 |
| 2026 | +5.7 | -8.3 | -30.6 | +7.9 | +0.9 | +8.7 | -12.1 | +21.7 | -23.0 |



